UPLOAD Filing
Anika Therapeutics, Inc.
Date: July 24, 2025 · CIK: 0000898437 · Accession: 0000000000-25-007779
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-14027
Letter
Re: Anika Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-14027 Dear Stephen Griffin:
July 24, 2025
Stephen Griffin Chief Financial Officer Anika Therapeutics, Inc. 32 Wiggins Avenue Bedford, MA 01730
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 24, 2025 Stephen Griffin Chief Financial Officer Anika Therapeutics, Inc. 32 Wiggins Avenue Bedford, MA 01730 Re: Anika Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-14027 Dear Stephen Griffin: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>